Orion Porfolio Solutions LLC Boosts Stake in Medtronic PLC $MDT

Orion Porfolio Solutions LLC boosted its stake in Medtronic PLC (NYSE:MDT) by 28.0% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 121,441 shares of the medical technology company’s stock after purchasing an additional 26,565 shares during the period. Orion Porfolio Solutions LLC’s holdings in Medtronic were worth $11,566,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in MDT. Brighton Jones LLC boosted its holdings in Medtronic by 1,368.0% during the 4th quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company’s stock valued at $3,194,000 after acquiring an additional 37,265 shares during the period. Sivia Capital Partners LLC increased its stake in Medtronic by 9.6% during the second quarter. Sivia Capital Partners LLC now owns 4,356 shares of the medical technology company’s stock worth $380,000 after purchasing an additional 381 shares during the period. NewSquare Capital LLC lifted its position in shares of Medtronic by 71.5% during the second quarter. NewSquare Capital LLC now owns 657 shares of the medical technology company’s stock worth $57,000 after purchasing an additional 274 shares in the last quarter. Ellevest Inc. boosted its stake in shares of Medtronic by 3.2% in the second quarter. Ellevest Inc. now owns 6,652 shares of the medical technology company’s stock valued at $580,000 after purchasing an additional 207 shares during the period. Finally, Atlantic Union Bankshares Corp boosted its stake in shares of Medtronic by 60.4% in the second quarter. Atlantic Union Bankshares Corp now owns 17,273 shares of the medical technology company’s stock valued at $1,506,000 after purchasing an additional 6,504 shares during the period. 82.06% of the stock is currently owned by institutional investors and hedge funds.

More Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Board approved a cash dividend of $0.71 for Q4 FY2026, reinforcing Medtronic’s long track record as a dividend grower and supporting income‑focused investor demand. Medtronic announces cash dividend for fourth quarter of fiscal year 2026
• Positive Sentiment: Medtronic launched the MiniMed Go Smart MDI system with the Simplera sensor in Europe, expanding its connected diabetes portfolio and addressing long‑term growth in continuous glucose monitoring and smart‑pen integration. Medtronic’s New MiniMed Go Highlights Digital Diabetes Push And Valuation Gap
• Positive Sentiment: Medtronic and GE HealthCare expanded their patient‑monitoring alliance, which could broaden distribution for products like Nellcor pulse oximetry and support recurring revenue streams. Medtronic, GE HealthCare expand patient monitoring alliance
• Positive Sentiment: Industry reports continue to rank Medtronic among leaders in biosensors and continuous glucose monitoring, supporting the company’s strategic position in a fast‑growing addressable market. Biosensors Company Evaluation Report 2025
• Neutral Sentiment: MiniMed priced its IPO at $20.00 per share for 28,000,000 shares — a procedural step that establishes a public valuation for the diabetes unit but doesn’t by itself show how Medtronic will deploy proceeds or adjust ownership. MiniMed announces pricing of initial public offering
• Negative Sentiment: MiniMed’s US IPO raised roughly $560 million — the market is interpreting the spin‑out as a catalyst for MDT selling pressure because it shifts future diabetes growth and cash flows away from the parent and may prompt portfolio rebalancing by investors. Medtronic’s diabetes unit MiniMed raises $560 million in US IPO

Medtronic Trading Down 2.8%

Shares of NYSE:MDT opened at $92.96 on Friday. Medtronic PLC has a 52 week low of $79.55 and a 52 week high of $106.33. The company’s 50 day moving average is $98.80 and its two-hundred day moving average is $96.95. The company has a market cap of $119.35 billion, a PE ratio of 25.89, a P/E/G ratio of 2.40 and a beta of 0.71. The company has a current ratio of 2.54, a quick ratio of 1.87 and a debt-to-equity ratio of 0.57.

Medtronic (NYSE:MDT) last posted its earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share for the quarter, topping the consensus estimate of $1.34 by $0.02. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The firm had revenue of $9.02 billion during the quarter, compared to analysts’ expectations of $8.89 billion. During the same quarter in the previous year, the business earned $1.38 earnings per share. The firm’s revenue was up 5.8% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Equities analysts predict that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, April 17th. Investors of record on Friday, March 27th will be given a $0.71 dividend. This represents a $2.84 dividend on an annualized basis and a dividend yield of 3.1%. The ex-dividend date of this dividend is Friday, March 27th. Medtronic’s dividend payout ratio (DPR) is 79.11%.

Insider Buying and Selling

In related news, EVP Harry Skip Kiil sold 52,524 shares of the business’s stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $97.71, for a total value of $5,132,120.04. Following the completion of the sale, the executive vice president directly owned 32,768 shares of the company’s stock, valued at $3,201,761.28. The trade was a 61.58% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.26% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several equities research analysts recently weighed in on MDT shares. William Blair raised shares of Medtronic from a “market perform” rating to an “outperform” rating in a research note on Tuesday, January 6th. JPMorgan Chase & Co. decreased their price target on shares of Medtronic from $105.00 to $100.00 and set a “neutral” rating for the company in a research report on Wednesday, February 18th. TD Cowen reaffirmed a “buy” rating on shares of Medtronic in a research report on Friday, November 14th. Wall Street Zen cut Medtronic from a “buy” rating to a “hold” rating in a research note on Sunday, March 1st. Finally, Needham & Company LLC decreased their target price on Medtronic from $121.00 to $120.00 and set a “buy” rating for the company in a report on Tuesday, February 17th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have given a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $110.74.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).